CYP51A1 and Chagas disease: The CYP51 inhibitors posaconazole (Noxafil, Merck) and ravuconazole (E1224, Eisai, Tokyo), which have undergone extensive pharmacological and toxicological optimization in antifungal programs, have demonstrated efficacy and curative activity in animal models of Chagas disease [22], and alleviated chronic Chagas disease in a patient with systemic lupus erythematosus [23,24].